Advancing Care in HER2-Positive GEA
Gastroesophageal adenocarcinoma (GEA), which includes stomach, gastroesophageal junction, and esophageal cancers, remains one of the most challenging cancers to treat. At Jazz, we are committed to advancing innovative research and exploring targeted therapies that have the potential to improve outcomes for people living with GEA. By deepening our understanding of the disease and its underlying biology, including HER2 expression, we aim to help redefine what is possible for patients and their families.
Featured
Recognizing the Signs: Nick’s Story of Early Symptoms, HER2 Testing and Hope
Nick shares his experience recognizing early signs of stomach cancer, navigating diagnosis, learning the importance of HER2 testing, and finding strength through treatment, family support, and hope for the future.
Navigating Next Steps After a HER2-Positive Advanced GEA Diagnosis
A HER2-positive gastroesophageal adenocarcinoma diagnosis can feel overwhelming, and preparing for conversations with a care team is a meaningful place to start. This guide can be used by people diagnosed with HER2+ advanced GEA and their caregivers to build a list of questions, take notes, and better understand a HER2+ diagnosis, treatment options, and available support.
Igniting Hope through GEA Care Progress
Martha Raymond, Founder & CEO of The Raymond Foundation and GI Cancers Alliance, expands on how the evolution of treatment in GI cancers, like gastroesophageal adenocarcinoma (GEA), ignites hope for patients, their care partners, and the entire community.
Fostering Community: GI Cancer Support
Harriet Patterson, Executive Director, Gastric Cancer Foundation, highlights the importance of community when navigating a GI cancer diagnosis, like gastroesophageal adenocarcinoma (GEA). As a patient advocate, she is driven to share trusted resources and provide support throughout the patient journey.
Life Doesn’t Stop with a GEA Diagnosis
Aki Smith, Founder and Executive Director, Hope for Stomach Cancer, encourages people living with gastroesophageal adenocarcinoma (GEA) cancer to keep going, keep living life – a shared philosophy as we continue to pursue new innovations in patient care.
Why Innovation Matters in First-Line HER2-Positive Gastroesophageal Adenocarcinoma
Chumi Khurana, Senior Vice President, Oncology Franchise Head
People diagnosed with locally advanced/metastatic HER2-positive gastroesophageal adenocarcinoma continue to face limited treatment options with the need to improve outcomes. Discover why innovation in the first-line setting remains essential to improving care.
The Full Burden of GEA
Amal Melhem-Bertrandt, Vice President and Oncology Therapy Area Head, Research and Development, sheds light on gastroesophageal adenocarcinoma (GEA) and the significant impact it has on both life expectancy and quality of life for people living with this difficult-to-treat cancer.
Learn how Jazz is shaping the future of targeted cancer care through HER2 science
The Potential of HER2-Targeted Therapies in Gastroesophageal Adenocarcinoma
HER2 plays an important role in cell growth and survival, but many cancers, including gastroesophageal adenocarcinoma (GEA), can overexpress this protein, leading to uncontrolled cell growth and impacting prognosis. While not everyone diagnosed with a GEA will be HER2-positive, it is helpful to test for HER2 as the presence of this protein can help inform the treatment approach.